Skip to textbook content
Doctor’s PassportTextbook
QuestionsFlashcardsBriefsDashboardAccount
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Obstetrics and gynaecology indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Epilepsy and antiseizure medicines

Obstetrics and gynaecology · UK scope · Sources checked 7 Sept 2026 · Clinical review pending

RapidFull
!
A prolonged convulsion requires immediate treatment

A convulsive seizure lasting five minutes or recurrent seizures without recovery is status epilepticus; a new seizure after 20 weeks or postpartum may instead be eclampsia.

Action: Call emergency medical and obstetric help, protect airway and circulation, check glucose and give rescue treatment according to the seizure plan. Assess urgently for eclampsia and other causes, using magnesium sulfate when eclampsia is suspected rather than assuming known epilepsy explains every event.

Overview

Maintain seizure control while reducing reproductive medicine risk, recognise changing antiseizure-drug exposure during pregnancy, and plan emergency, intrapartum and postnatal care.

For most patients, pregnancy with epilepsy can be managed successfully with coordinated neurological and obstetric care. The essential comparison is between the risks of a particular medicine and the risks of uncontrolled seizures, injury, hypoxia and epilepsy-related death. A patient who stops treatment because of fear may become less safe without meaningfully reversing an exposure that has already occurred. Ask what they have actually taken, what they have missed and what concerns prompted any change.

Before conception confirm the epilepsy syndrome, seizure types, recent control, previous treatment failures and rescue plan. An apparently simple switch to a medicine with more reassuring reproductive data may be ineffective for that patient's epilepsy. When change is appropriate, complete it gradually and establish stability before conception if possible. Discuss contraception, interactions, folic acid, sleep, alcohol, adherence, driving advice and practical support. Record both the patient's preferences and the reasons for the agreed regimen.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Obstetrics and gynaecologyOriginal SBA

Unexpected pregnancy on valproate

A woman with difficult-to-control epilepsy discovers she is six weeks pregnant while taking valproate. She has not missed doses and is currently well. What should she be advised to do next?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Obstetrics and gynaecology topics →
Sources and review status7 sources · checked 7 Sept 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.

  • NICE NG217: Treatment safety and pregnancy monitoring
  • NICE NG217: Status epilepticus and prolonged seizures
  • MHRA: Valproate reproductive risks and current requirements
  • MHRA: Topiramate Pregnancy Prevention Programme
  • MHRA: Antiseizure medicines pregnancy safety review
  • Levetiracetam 500 mg tablets: current SmPC
  • Lorazepam Macure injection: SmPC

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

MHRA pregnancy evidence is most reassuring for lamotrigine and levetiracetam among commonly used options, while several other agents carry higher or less certain malformation, growth or developmental risks. These comparisons do not establish a risk-free drug. Monotherapy is preferred when effective, but a necessary combination may be safer than recurrent convulsive seizures. Explain risk in absolute terms where good data exist and distinguish evidence about malformations from the less complete evidence about long-term development.

Valproate requires particularly careful governance. It must not be newly initiated in a person under 55 unless two specialists independently document that alternatives are ineffective or not tolerated, or compelling reasons establish that reproductive risks do not apply. For women and girls who could become pregnant, the Pregnancy Prevention Programme and required specialist review remain central. During pregnancy for epilepsy it is reserved for circumstances where no suitable alternative exists. Suspected pregnancy triggers urgent specialist contact, not an unsupported instruction to stop immediately.

Topiramate has its own Pregnancy Prevention Programme. It is contraindicated in pregnancy for migraine prevention and should not be used for epilepsy during pregnancy unless no other suitable treatment is available. Ensure the indication is known before applying an exception. Discuss effective contraception, pregnancy testing and annual risk review according to current MHRA materials. Folate supplementation is appropriate but should never be described as cancelling a teratogenic medicine's risk.

Pregnancy changes renal clearance, distribution and metabolism, so a previously effective dose may produce a lower concentration, particularly with lamotrigine or levetiracetam. A baseline obtained when the patient is stable before conception can be more useful than a population laboratory range. Monitor according to seizure history and the drug-specific plan; ask about adherence and sample timing. A result matters only if someone reviews it, relates it to symptoms and arranges adjustment or follow-up.

Any new seizure needs fresh assessment. Eclampsia, hypoglycaemia, electrolyte disturbance, infection, stroke and cerebral venous thrombosis can occur in someone who already has epilepsy. A prolonged convulsion requires immediate rescue treatment, with the total number of benzodiazepine doses counted across home, ambulance and hospital care. Persistent seizures after two doses require senior-led intravenous second-line treatment and airway planning. Do not withhold emergency treatment merely because the medicine has pregnancy cautions.

Labour and early parenting create practical triggers: missed doses, vomiting, pain and sleep deprivation. Maintain scheduled medication, provide an alternative route if oral dosing is impossible and have the rescue plan accessible. Epilepsy alone does not automatically require caesarean birth. After delivery, drug clearance can return towards baseline quickly, creating toxicity if an increased antenatal dose is continued unchanged. Discuss infant feeding using the actual drug and dose, monitor the infant where appropriate and plan safe bathing, carrying and sleep support.

Key points

  • Do not stop antiseizure medication abruptly when pregnancy is discovered; arrange urgent individual review of seizure and fetal risks.
  • Optimise treatment before conception where possible, favouring an effective lower-risk single drug at the lowest dose that maintains control.
  • Lamotrigine and levetiracetam have comparatively reassuring pregnancy data, but suitability depends on seizure type, prior response and individual adverse effects.
  • Prescribe folic acid 5 mg orally daily before conception through 12 weeks for patients taking relevant antiseizure medicines.
  • Valproate has major reproductive risks and strict MHRA restrictions, including two-specialist agreement for new initiation below age 55 and Pregnancy Prevention Programme requirements where applicable.
  • Topiramate is contraindicated for migraine prevention in pregnancy and for epilepsy in pregnancy unless no suitable alternative exists; a Pregnancy Prevention Programme applies to those who could become pregnant.
  • Obtain a useful preconception drug-level baseline when monitoring is indicated, and act on clinical and concentration changes during pregnancy.
  • If doses increased during pregnancy, plan reduction towards preconception doses in the first days after birth with monitoring for toxicity and breakthrough seizures.

Aetiology

01

Established epilepsy syndrome

Genetic, structural or other epilepsy causes determine seizure type and drug response, so reproductive planning must account for the individual's history rather than a generic drug hierarchy.

02

Pregnancy-related loss of control

Vomiting, missed medication, sleep disruption and altered drug clearance can reduce seizure control without a change in the underlying epilepsy.

Pathophysiology

  1. 1
    Altered medicine exposure

    Increased renal elimination and hepatic metabolism during pregnancy can lower concentrations of some antiseizure medicines, requiring monitoring and individual dose adjustment.

  2. 2
    Convulsive physiological stress

    Prolonged convulsions impair oxygenation, increase metabolic demand and risk trauma, threatening maternal function and the fetus through disrupted maternal physiology.

  3. 3
    Fetal medicine exposure

    Antiseizure medicines cross the placenta to differing degrees and can affect development, with risk varying by drug, dose and combination rather than epilepsy alone.

Clinical features and red flags

Loss of previous seizure control

A change in frequency, duration or seizure type may indicate falling drug exposure, missed doses, illness or a new diagnosis.

Medication concentration change

A lower level relative to a stable preconception baseline can support a pharmacokinetic explanation, especially when sample timing and adherence are consistent.

High-risk reproductive exposure

Valproate or topiramate use requires indication-specific specialist review and current regulatory safeguards rather than generic reassurance.

Postnatal toxicity

Dizziness, diplopia, ataxia, marked sedation or nausea after an antenatal dose increase may signal rising concentrations as pregnancy-related clearance resolves.

Red flags requiring action

  • A seizure lasting at least five minutes, repeated convulsions without recovery or persistent reduced consciousness requires emergency resuscitation and hospital treatment.
  • New headache, visual disturbance, hypertension or epigastric pain accompanying a seizure raises concern for eclampsia even with a prior epilepsy diagnosis.
  • Pregnancy while taking valproate or topiramate requires urgent specialist review, but abrupt self-discontinuation can precipitate dangerous seizures.

Investigations

  1. 01
    Detailed seizure and treatment historyFirst step
    Why
    Define control, syndrome, adherence and exposure before changing medication.
    Interpretation and limitations
    Witness accounts and rescue-treatment records help distinguish seizure types and identify whether the recent event differs from the patient's usual pattern.
  2. 02
    Selected antiseizure-drug concentrations
    Why
    Compare exposure with an individual baseline when pregnancy monitoring is indicated.
    Interpretation and limitations
    Interpret samples with dose timing, adherence, seizure control and pregnancy-related protein binding or clearance changes; act on relevant findings.
  3. 03
    Glucose, electrolytes and acute illness tests
    Why
    Identify reversible seizure precipitants and metabolic complications.
    Interpretation and limitations
    A normal glucose does not exclude eclampsia or structural brain disease; testing accompanies emergency treatment rather than postponing it.
  4. 04
    Blood pressure, urine and pre-eclampsia blood tests
    Why
    Assess obstetric causes of seizures after mid-pregnancy or postpartum.
    Interpretation and limitations
    Known epilepsy does not rule out eclampsia, and proteinuria need not be present for serious pre-eclamptic disease.
  5. 05

Differential diagnosis

01

Eclampsia

A new seizure after mid-pregnancy or postpartum may be obstetric even in a patient with epilepsy; assess pressure, symptoms and organ involvement urgently.

02

Metabolic or structural emergency

Hypoglycaemia, electrolyte disturbance, intracranial haemorrhage or cerebral venous thrombosis can cause seizures and require treatment beyond adjustment of chronic antiseizure medication.

03

Syncope or functional seizures

Transient loss of consciousness and non-epileptic events can resemble epilepsy; careful history and specialist assessment reduce inappropriate medication escalation after uncertain episodes.

Management

01Preconception planningAgree a stable effective regimenFirst stepA patient with epilepsy is considering pregnancy or needs reproductive counselling.+
  1. 1Review seizure syndrome, recent control, prior medicine trials and reproductive preferences with an epilepsy specialist.
  2. 2Optimise an effective regimen before conception where feasible and document folic acid, contraception and applicable MHRA safeguards.
  3. 3Obtain relevant baseline levels and provide written instructions for a positive pregnancy test, missed doses and prolonged seizures.
02Antenatal changeRespond to pregnancy or breakthrough seizuresPregnancy is confirmed, medication cannot be retained or seizure control deteriorates.+
  1. 1Arrange prompt neurology–maternity review without abruptly withdrawing essential treatment, especially with valproate or topiramate exposure.
  2. 2

Complications

01

Status and injury

Prolonged seizures, aspiration, falls and hypoxia can harm the patient and pregnancy, making adherence, rescue planning and timely treatment central to care.

02

Reproductive medicine effects

Certain exposures increase congenital-malformation or developmental risk, requiring informed counselling, appropriate screening and specialist consideration of safer effective alternatives.

03

Postnatal safety difficulties

Sleep deprivation, medicine toxicity and breakthrough seizures can complicate infant care, so practical support and a written postnatal plan are important preventive measures.

Monitoring and follow-up

  • At each contact document seizure frequency, missed doses, vomiting, sleep disruption and any new adverse effects.
  • Make the drug-concentration reviewer and action threshold explicit so abnormal results are not filed without clinical response.
  • Review the antenatal dose-increase and postnatal reduction plan before delivery, including the date of the next level when indicated.
  • Observe breastfed infants for unusual sedation, poor feeding or inadequate weight gain when maternal medicine exposure warrants it.
  • Ensure ongoing specialist and primary-care follow-up covers contraception, driving requirements, mental health and epilepsy-related safety.

Special situations

Do not chase a population range

An individual's stable preconception concentration can be a more useful treatment reference than an isolated result compared with a broad laboratory interval.

Emergency treatment has a different balance

Prolonged maternal convulsions threaten both patient and fetus, making prompt rescue medication appropriate even when routine exposure would require reproductive counselling.

Folate is not an antidote

High-dose folic acid is preventive care, but cannot be presented as neutralising the risks of valproate or other harmful exposures.

Postnatal doses need active review

A dose increase that prevented antenatal seizures can become excessive after delivery as clearance normalises, especially for medicines with substantial pregnancy-related changes.

Common pitfalls

  1. 01

    Advising immediate unsupervised withdrawal of an antiseizure medicine at a positive pregnancy test.

  2. 02

    Assuming lamotrigine or levetiracetam is effective for every seizure syndrome solely because pregnancy data are more reassuring.

  3. 03

    Failing to check the indication when a pregnant patient reports topiramate use.

  4. 04

    Ordering drug levels without naming who will review and act on them.

  5. 05

    Attributing a postpartum seizure automatically to established epilepsy.

  6. 06

    Repeating benzodiazepines without counting doses already given by family or ambulance staff.

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Increasing seizures, inability to retain medication or a sudden fall in a relevant drug concentration requires prompt epilepsy-team assessment.
EEG or brain imaging when clinically indicated
Why
Clarify a new epilepsy diagnosis or an atypical neurological event.
Interpretation and limitations
Persistent focal signs or impaired consciousness may require urgent imaging; a routine normal EEG does not exclude epilepsy.
Assess adherence, vomiting, sleep, drug levels and competing obstetric or neurological diagnoses before attributing every event to dose failure.
  • 3Adjust treatment through the specialist plan and communicate the new dose, next test and clinician responsible for review.
    • 03Birth and postnatal safetyPrevent omissions and reverse temporary dose increasesLabour is approaching or an antenatal medication increase must be reviewed after delivery.+
    1. 1AlternativeEnsure scheduled medication continues during labour, with rescue treatment and a non-oral alternative available when necessary.
    2. 2Begin the agreed postnatal dose adjustment in the first days after birth, watching for toxicity and loss of seizure control.
    3. 3Discuss breastfeeding, infant sedation or feeding concerns, sleep protection and practical childcare safety with the patient and support network.
    Key medicines and prescribing safety3 treatments · regimens, roles and cautions+
    Provides high-dose folate prevention where antiseizure treatment increases folate-related reproductive risk.

    Folic acid with antiseizure treatment

    Prescribe 5 mg orally once daily before conception and continue until 12 completed weeks of pregnancy, ideally starting several months before trying to conceive.

    Folic acid does not eliminate drug-related congenital or neurodevelopmental risk and must accompany, rather than replace, medication review.

    A comparatively well-studied pregnancy option when it effectively treats the patient's seizure syndrome.

    Levetiracetam for an appropriate epilepsy syndrome

    The cited adult SmPC therapeutic starting dose is 500 mg orally twice daily, with lower initial dosing possible for tolerability and specialist titration up to 1,500 mg twice daily; an established pregnancy regimen is adjusted to clinical control and the individual monitoring plan.

    Adjust for renal impairment, assess mood or behavioural adverse effects and monitor pregnancy-related concentration changes; never substitute it abruptly for another established antiseizure medicine.

    Emergency seizure termination when intravenous access is available and the status pathway applies.

    Lorazepam for convulsive status epilepticus

    Give 4 mg by slow intravenous injection with immediate resuscitation facilities for adult convulsive status; NICE permits one further benzodiazepine dose if the seizure persists five to ten minutes after the first, counting any prehospital doses.

    Monitor ventilation and blood pressure, account for all prior benzodiazepines and escalate after two doses; suspected eclampsia also needs magnesium and urgent obstetric treatment.